Picture of Bristol-Myers Squibb logo

CELG RT — Bristol-Myers Squibb News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapSuper Stock

Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease

BRIEF-Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease

- Bristol-Myers Squibb Company BMY.N:

  • BRISTOL MYERS SQUIBB PRESENTS FIRST CLINICAL DATA FROM TWO PHASE 3 STUDIES IN THE ADEPT PROGRAM EVALUATING KARXT FOR PSYCHOSIS ASSOCIATED WITH ALZHEIMER’S DISEASE

  • BRISTOL-MYERS SQUIBB COMPANY - ADEPT-1 SHOWS MEAN REDUCTION OF 1.9 POINTS ON CGI-S SCORE

  • BRISTOL-MYERS SQUIBB COMPANY - ADEPT-1 SHOWS MEAN REDUCTION OF 12.0 POINTS ON NPI-C H+D SCALE

  • BRISTOL-MYERS SQUIBB COMPANY: KARXT WAS GENERALLY WELL TOLERATED ACROSS BOTH STUDIES WITH NO NEW SAFETY SIGNALS IDENTIFIED

  • BRISTOL-MYERS SQUIBB COMPANY - ADEPT-3 SHOWS MEAN REDUCTION OF 5.1 POINTS ON NPI-C H+D SCALE, 0.8 ON CGI-S

Source text: ID:nBw583ZWwa

Further company coverage: BMY.N


((Reuters.Briefs@thomsonreuters.com;))

Recent news on Bristol-Myers Squibb

See all news